Thyrocare Technologies Ltd - 539871 - Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed the certificate under Regulation 7(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2022. Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ramjee DoraiDesignation :- Company Secretary and Compliance Officer Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with effect from April 01, 2022, and would be re-opened after 48 hours of date of announcement / declaration of Audited Financial Results for the Financial Year ended March 31, 2022. Thyrocare Technologies Ltd - 539871 - Pursuant To Regulation 30 And Regulation 31(8)(D) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We hereby inform you that the Company has received approval from the National Stock Exchange of India and BSE Ltd. for reclassification of the outgoing Promoters and Promoter Group shareholders from Promoter category to public category in accordance with the Regulation 31A (10) of SEBI (Listing and Disclosure requirements), Regulation 2015 Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 17, 2022 for Docon Technologies Pvt Ltd Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 17, 2022 for Docon Technologies Pvt Ltd Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Axis Trustee Services Ltd Thyrocare Technologies Ltd - 539871 - Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Judgement by the Income Tax Appellate Tribunal (the 'ITAT') in favour of the Company in the tax litigations with Income Tax Department on non-deduction of TDS from the amount payable/paids by the Franchisees. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have published the unaudited financial results for the quarter/ 9 months ended 31-12-2021 in Free Press Journal (English) and Pudhari (Marathi). The same has been made available on the Company''s website www.thyrocare.com
